Vivos Therapeutics (VVOS) Return on Equity (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Return on Equity data on file, last reported at 0.19% in Q1 2026.

• Quarterly Return on Equity rose 21.0% year-over-year to 0.19% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.19% (up 21.0% YoY) and the FY2025 annual result came in at 0.07%, down 4.0% from the prior year.
• Return on Equity improved to 0.19% in Q1 2026 per VVOS's latest filing, from 0.43% in the prior quarter.
• Across five years, Return on Equity topped out at 0.19% in Q1 2026 and bottomed at 0.43% in Q4 2025.
• The 5-year median for Return on Equity is 0.02% (2022), against an average of 0.04%.
• The widest annual swing landed in 2025, when Return on Equity sank 42 bps; it then grew 21 bps in 2026.
• Tracing VVOS's Return on Equity over 5 years: stood at 0.03% in 2022, then jumped by 106 bps to 0.0% in 2023, then sank by 862 bps to 0.01% in 2024, then tumbled by 2917 bps to 0.43% in 2025, then jumped by 143 bps to 0.19% in 2026.
• Per Business Quant, the three latest VVOS Return on Equity figures stand at 0.19% (Q1 2026), 0.43% (Q4 2025), and 0.05% (Q3 2025).

Peer Comparison